Core Insights - Annovis Bio Inc. is a late-stage clinical drug platform company focused on developing therapies for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease [1][4] - The CEO, Dr. Maria Maccecchini, will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference, discussing the company's advancements and the pivotal Phase 3 trial for its drug, buntanetap [1][2] Company Overview - Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to addressing neurodegeneration in diseases like Alzheimer's and Parkinson's [4] - The company aims to develop innovative therapies that enhance patient outcomes and quality of life [4] Conference Details - The Oppenheimer's Annual Healthcare Life Sciences Conference is a significant event that gathers leading companies and investors in the healthcare and life sciences sectors [3] - The conference features presentations from industry executives, offering insights into current trends, innovations, and investment opportunities [3]
Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference